Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Tophi can affect any joint, including in the fingers and thumbs. It is a sign of advanced or chronic gout. When tophi affect the small joints of the thumbs and fingers, physical changes and ...

The third phase, inter-critical gout, is a period between acute attacks when the patient is symptom-free. Finally, chronic ...

One surprising link Dr. Rothschild highlighted is the strong correlation between CKD and gout. “Chronic kidney disease and gout are more connected than many people realize. In fact, 1 in 4 ...

A new study published in the recent issue of International Journal of Rheumatic Diseases showed that the need for greater ...

Sweden’s Sobi has kicked off a rolling biologics license application in the US for SEL-212, vying to become a new option for patients with refractory chronic gout that doesn’t respond to ...

Arthrosi Therapeutics doses first patient in replicate pivotal phase 3 REDUCE 1 trial of lead compound AR882: San Diego Wednesday, March 19, 2025, 11:00 Hrs [IST] Arthrosi Therape ...

Febuxostat is a second-line option for patients with gout who are unable to take allopurinol due to hypersensitivity, intolerance, or lack of efficacy in achieving a target serum uric acid ...